Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

3.4K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.4K
iPS Cell Differentiation01:22

iPS Cell Differentiation

3.2K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.2K
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

2.7K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.7K
Chromatin Modification in iPS Cells01:32

Chromatin Modification in iPS Cells

2.2K
Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
2.2K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

84.3K
Overview
84.3K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

9.1K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Non-human primate preclinical model revealed the feasibility and short-term safety of iPSC-derived innate-like T cells in autologous transplantation.

Frontiers in immunology·2026
Same author

Generation of therapeutic T cells from human induced pluripotent stem cells.

Inflammation and regeneration·2026
Same author

IL-15 and IL-21 synergy improves anti-tumor efficacy of iPSC-derived cytotoxic T cells in solid tumors.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Stress-induced CXCL13 regulates pancreatic exocrine homeostasis, age-related chronic inflammation, and cancer progression.

Science advances·2026
Same author

Ventricular fibrillation triggered by recurrent hypoglycemia in a patient with insulinoma associated with MEN1: case report and review of literature.

Endocrine journal·2026
Same author

Non-human primate preclinical model revealed the feasibility and short-term safety of iPSC-derived innate-like T cells in autologous transplantation.

Frontiers in immunology·2026

Related Experiment Video

Updated: Feb 13, 2026

Isolation of Functional Cardiac Immune Cells
07:26

Isolation of Functional Cardiac Immune Cells

Published on: December 5, 2011

15.5K

[Immune cell therapy using iPS cells].

Hisashi Yano1,2, Shin Kaneko1

  • 1Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|March 9, 2018
PubMed
Summary

Reprogramming donor T cells into induced pluripotent stem cells (T-iPS) and differentiating them into rejuvenated T cells (T-iPS-T) overcomes limitations in adoptive cell therapy. This approach provides an unlimited source of high-quality, genetically engineered T cells for cancer treatment.

Keywords:
Adoptive immunotherapyT-iPS-TTCR/CARiPS cells

More Related Videos

MicroRNA Expression Profiles of Human iPS Cells, Retinal Pigment Epithelium Derived From iPS, and Fetal Retinal Pigment Epithelium
10:19

MicroRNA Expression Profiles of Human iPS Cells, Retinal Pigment Epithelium Derived From iPS, and Fetal Retinal Pigment Epithelium

Published on: June 24, 2014

11.9K
Assessing Stem Cell DNA Integrity for Cardiac Cell Therapy
10:16

Assessing Stem Cell DNA Integrity for Cardiac Cell Therapy

Published on: January 25, 2019

8.2K

Related Experiment Videos

Last Updated: Feb 13, 2026

Isolation of Functional Cardiac Immune Cells
07:26

Isolation of Functional Cardiac Immune Cells

Published on: December 5, 2011

15.5K
MicroRNA Expression Profiles of Human iPS Cells, Retinal Pigment Epithelium Derived From iPS, and Fetal Retinal Pigment Epithelium
10:19

MicroRNA Expression Profiles of Human iPS Cells, Retinal Pigment Epithelium Derived From iPS, and Fetal Retinal Pigment Epithelium

Published on: June 24, 2014

11.9K
Assessing Stem Cell DNA Integrity for Cardiac Cell Therapy
10:16

Assessing Stem Cell DNA Integrity for Cardiac Cell Therapy

Published on: January 25, 2019

8.2K

Area of Science:

  • Immunology
  • Cell Therapy
  • Cancer Research

Background:

  • Adoptive cell therapy (ACT) shows promise for melanoma and hematological malignancies.
  • Current ACT is limited by the availability of high-quality T cells, as tumor-specific T cells are often exhausted.
  • Enhanced T cell quality correlates with improved ACT efficacy.

Purpose of the Study:

  • To overcome the limitations of T cell availability and quality in ACT.
  • To develop a method for generating rejuvenated, antigen-specific T cells from induced pluripotent stem cells (iPSCs).
  • To explore the potential of iPSCs as an unlimited source for genetically engineered T cell therapies.

Main Methods:

  • Reprogramming of donor T cells into induced pluripotent stem cells (T-iPS).
  • Differentiation of T-iPS cells into rejuvenated, antigen-specific T cells (T-iPS-T).
  • Generation of genetically engineered T cells (e.g., TCR-T, CAR-T, PD-1 knockout) from iPSCs.

Main Results:

  • Successful reprogramming of T cells into T-iPS cells.
  • Generation of rejuvenated, antigen-specific T-iPS-T cells.
  • Demonstration of iPSCs as a versatile platform for producing various types of engineered T cells.

Conclusions:

  • T-iPS cell technology offers a solution to the scarcity of high-quality T cells for ACT.
  • This approach enables the production of rejuvenated and genetically modified T cells for enhanced cancer immunotherapy.
  • Induced pluripotent stem cells hold "infinite" potential for advancing immune cell therapies.